drugset / Trial / NCT06050941
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
NaSingle-groupOpen-labelTreatment
Summary
Reduced intensive 3 + 5 idarubicin and cytarabine chemotherapy plus venetoclax as first-line treatment for adults with acute myeloid leukaemia and high-risk myelodysplastic syndrome
Timeline
- Start
- 2024-04-02
- Primary completion
- 2026-04-02
- Completion
- 2027-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 60 mg/m2 | — |
| Subject | Idarubicin | Small molecule | 6 mg/m2 | — |